<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744718</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000878-20</org_study_id>
    <secondary_id>S-20080033</secondary_id>
    <secondary_id>2612-3754</secondary_id>
    <nct_id>NCT00744718</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Carboplatin for Patients With Ovarian Cancer</brief_title>
  <official_title>Bevacizumab and Carboplatin for Patients With Platin Resistant Epithelial Ovarian Cancer. A Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients
      with platin resistant ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of first treatment until date of verified progression or death. 12 months of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first treatment until death. Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 9 weeks until progression or death. Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>From date of first documented response until date of progression. Up to 12 months.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">73</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10 mg/kg every 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 every 5 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically verified epithelial ovarian cancer, primary tubae- or primary
             peritoneal cancer (Stage I-IV)

          2. Carboplatin resistant ovarian cancer previously treated with a maximum of three
             different cytostatic regimens (single substance or in combination).

          3. Age ≥ 18 years.

          4. Performance status 0-2.

          5. Measurable disease according to CA125 GCIG criteria (Gynaecologic Cancer Intergroup)
             or RECIST (Response Evaluation Criteria in Solid Tumors) (See appendix I+II)

          6. Adequate bonemarrow, liver and kidney function and coagulation parameters (within
             seven days of start of treatment).

          7. ANC ≥ 1.5*109

          8. Thrombocytes ≥ 100*10^9/L

          9. Haemoglobin (Hb) ≥ 6 mmol/l

         10. Se-bilirubin (BR) ≤ 1.5*ULN (Upper Limit of Normal)

         11. Se-transaminase ≤ 2.5*ULN

         12. Se-creatinin ≤ 1.5*ULN

         13. Urin stix for protein &lt;2+ (If stix shows protein ≥2+ urin must be measured 24 hours
             where the protein content must be under 1 g.)

         14. INR ≤1.5

         15. APTT ≤ 1.5*ULN

         16. Signed informed consent form.

        Exclusion Criteria:

          1. Patients who have received other types of experimental treatment or participated in a
             clinical study less than 28 days prior to this study.

          2. Pregnant or breastfeeding women. A negative pregnancy test is mandatory for fertile
             women.

          3. Fertile women, who do not wish to use safe contraception (e.g., birth control pills,
             coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and
             transdermal deposit band-aid).

          4. Untreated bowel obstruction or massive gastrointestinal tumors verified by CT scan.

          5. Other present or previous malignant disease apart from curatively treated non-melanoma
             skin cancer or other types of cancer with minimal risk of relapse.

          6. CNS-metastases.

          7. Underlying medical disease not adequately treated (diabetes, cardiovascular disease).

          8. Uncontrolled hypertension (persistent BP &gt; 150/100 despite antihypertensive
             treatment).

          9. Surgery incl. open biopsy less than 4 weeks before expected first dose of Bevacizumab.

         10. Patients with non-healing wounds or fractures.

         11. Previous cerebrovascular attack (TVA), transient ischaemic attack (TIA) or
             subarachnoidal bleeding (SAH) within last six months.

         12. Thromboembolic or haemorrhagic disease in the anamnesis.

         13. Clinically significant cardiovascular disease including Myocardial infarction or
             unstable angina less than 6 months prior to treatment

               -  New York heart Association NYHA class ≥ 2

               -  Poorly controlled cardial arrythmia despite medical treatment

               -  Peripheral vascular disease, grade 3 or above.

         14. Present or previous chronical use of Aspirin (less than 10 days before start of
             treatment) Aspirin &gt; 325 mg daily.

         15. Present or recent use of full dose oral or parenteral anticoagulant or thrombolytic
             medicine.

         16. Preexisting neuropathy, sensoric or motoric ≥ grade 2.

         17. Decreased hearing.

         18. Bleeding tumor.

         19. Hypersensitivity to the active substance or one or more of the other substances
             contained in the protocol drugs.

         20. Hypersensitivity to products from ovarian cells (CHO) from Chinese hamster or other
             recombinant or humanized antibodies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

